Autolus Therapeutics plc (6A3A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has a cash flow conversion efficiency ratio of -0.378x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-67.32 Million ≈ $-78.71 Million USD) by net assets (€178.13 Million ≈ $208.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Autolus Therapeutics plc balance sheet quality to measure how much of total assets are equity-financed.
Autolus Therapeutics plc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Autolus Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore 6A3A debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Autolus Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Autolus Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Studio City International Holdings Ltd
NYSE:MSC
|
0.015x |
|
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas
SA:AGRO3
|
0.060x |
|
Xunlei Ltd Adr
NASDAQ:XNET
|
0.002x |
|
Rice Acquisition Corporation 3
NYSE:KRSP
|
-0.001x |
|
Zhejiang Giuseppe Garment Co Ltd
SHE:002687
|
0.041x |
|
Padini Holdings Bhd
KLSE:7052
|
0.115x |
|
Hotel Majestic Cannes
PA:MLHMC
|
0.033x |
|
Jiangsu Tongda Power Technology Co Ltd
SHE:002576
|
0.007x |
Annual Cash Flow Conversion Efficiency for Autolus Therapeutics plc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics plc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Autolus Therapeutics plc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €178.13 Million ≈ $208.25 Million |
€-283.57 Million ≈ $-331.52 Million |
-1.592x | -229.79% |
| 2024-12-31 | €427.32 Million ≈ $499.59 Million |
€-206.27 Million ≈ $-241.15 Million |
-0.483x | +63.04% |
| 2023-12-31 | €111.47 Million ≈ $130.32 Million |
€-145.59 Million ≈ $-170.21 Million |
-1.306x | -247.32% |
| 2022-12-31 | €298.67 Million ≈ $349.18 Million |
€-112.31 Million ≈ $-131.30 Million |
-0.376x | +0.04% |
| 2021-12-31 | €313.32 Million ≈ $366.30 Million |
€-117.86 Million ≈ $-137.79 Million |
-0.376x | +32.91% |
| 2020-12-31 | €210.03 Million ≈ $245.55 Million |
€-117.76 Million ≈ $-137.67 Million |
-0.561x | -40.79% |
| 2019-12-31 | €254.84 Million ≈ $297.93 Million |
€-101.48 Million ≈ $-118.65 Million |
-0.398x | -139.23% |
| 2018-12-31 | €255.47 Million ≈ $298.67 Million |
€-42.52 Million ≈ $-49.72 Million |
-0.166x | -45.09% |
| 2017-12-31 | €142.60 Million ≈ $166.72 Million |
€-16.36 Million ≈ $-19.13 Million |
-0.115x | -- |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more